Mańkowska-Wierzbicka Dorota, Karczewski Jacek, Poniedziałek Barbara, Grzymisławska Małgorzata, Staszewski Rafał, Królczyk Aleksandra, Dobrowolska Agnieszka, Grzymisławski Marian
Department of Gastroenterology, Human Nutrition and Internal Disases, Poznan University of Medical Sciences.
Department of Environmental Medicine, Poznan University of Medical Sciences.
Postepy Hig Med Dosw (Online). 2016 Nov 7;70(0):1124-1130. doi: 10.5604/17322693.1223798.
The study aimed to evaluate high-sensitivity CRP (hsCRP) as a diagnostic and predictive marker in patients with inflammatory bowel disease (IBD).
MATERIAL/METHODS: Medical history of 106 patients with IBD revealed hsCRP concentrations at diagnosis and during the follow-up period.
The study showed that the majority of investigated patients had elevated hsCRP concentrations at diagnosis, although the mean concentration was much higher in the group of patients with Crohn's disease (CD) than the group with ulcerative colitis (UC) (P<0.001). The overall decrease in mean hsCRP concentration observed during the follow-up period was larger in the group of CD patients. The analysis showed a correlation between hsCRP concentrations at diagnosis and risk of surgery in the group of CD patients (r=0.408, P=0.002), but not in the group of UC patients. In a logistic regression analysis, surgery in CD patients was associated with age (OR: 0.89, 95% CI: 0.8-1.0, P=0.05) and hsCRP concentration (OR: 1.02, 95% CI: 1.0-1.04, P=0.03) at diagnosis.
HsCRP might be a useful diagnostic marker in differentiating active IBD from other diseases. Particularly important however seems to be the predictive value of hsCRP at diagnosis in prognosing the clinical outcome of the disease in CD patients.
本研究旨在评估高敏C反应蛋白（hsCRP）作为炎症性肠病（IBD）患者的诊断和预测标志物。
材料/方法：106例IBD患者的病史显示了诊断时及随访期间的hsCRP浓度。
研究表明，大多数被调查患者在诊断时hsCRP浓度升高，尽管克罗恩病（CD）组的平均浓度远高于溃疡性结肠炎（UC）组（P<0.001）。随访期间观察到的CD患者组平均hsCRP浓度总体下降幅度更大。分析显示，CD患者组诊断时的hsCRP浓度与手术风险之间存在相关性（r=0.408，P=0.002），而UC患者组则无此相关性。在逻辑回归分析中，CD患者的手术与诊断时的年龄（OR：0.89，95%CI：0.8-1.0，P=0.05）和hsCRP浓度（OR：1.02，95%CI：1.0-1.04，P=0.03）相关。
HsCRP可能是区分活动性IBD与其他疾病的有用诊断标志物。然而，特别重要的似乎是诊断时hsCRP在预测CD患者疾病临床结局方面的预测价值。
